Biocad enters deal for exporting rituximab biosimilar to Turkey

Biocad, one of Russia’s leading biotechnology companies, has signed a definitive agreement on the export of rituximab active pharmaceutical ingredients (APIs) produced by the company with Kocak Farma, a leading Turkish drugmaker with strong presence in the area of oncology.

According to the accord, Biocad will supply rituximab, said to be a biosimilar of Roche’s blockbuster cancer drug Rituxan/MabThera, to Kocak Farma for five years. Biocad will give its Turkish partner exclusive rights to import the API, to produce the finished dosage forms locally, as well as to distribute and sell rituximab in Turkey. Kocak, in turn, will have the rights for distribution and sales of finished dosage forms of the drug in Turkey under its own brand.

Preparing for Russian marketing authorization